Last reviewed · How we verify
SAL067
SAL067 is a small-molecule inhibitor targeting a specific kinase or receptor involved in disease pathogenesis.
At a glance
| Generic name | SAL067 |
|---|---|
| Also known as | SAL067 Group |
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Without publicly available detailed mechanism information, SAL067's exact molecular target and pathway remain unclear. As a Phase 3 asset from Shenzhen Salubris Pharmaceuticals, it is likely a rationally designed small molecule for a specific therapeutic indication, but the precise mechanism requires access to clinical trial data or company disclosures.
Approved indications
Common side effects
Key clinical trials
- The Pharmacokinetics Study of Fotagliptin in Patients with Different Degrees of Renal Insufficiency (PHASE1)
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled by Metformin (PHASE3)
- SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAL067 CI brief — competitive landscape report
- SAL067 updates RSS · CI watch RSS
- Shenzhen Salubris Pharmaceuticals Co., Ltd. portfolio CI